comprehensive -WSS

comprehensive

author：knowledge 2025-09-30 12:10:52 - browse：7394

Novo Nordisk Denmark — LISELOTTE SABROE/AFP/Getty Images

An oral version of semaglutide, the drug marketed as Ozempic and Wegovy, led to dramatic weight loss in a trial enrolling people with obesity, manufacturer Novo Nordisk said Monday, data that could bolster what is already a blockbuster medicine.

In the study, which enrolled nearly 700 adults classified as having overweight or obesity, patients treated with a daily semaglutide tablet lost 15.1% of their body weight over the course of 17 months, while those on placebo lost 2.4%, Novo Nordisk said. The result is comparable to weekly injections of Wegovy, which in an earlier study led to 14.9% weight loss over the same period of time. In both studies, the most common side effects were gastrointestinal distress, with the majority of cases graded mild or moderate, the company said.

Novo Nordisk said it plans to submit oral semaglutide for U.S. and E.U. approvals later this year. A lower-dose version of the drug is already approved as a treatment for type 2 diabetes under the brand name Rybelsus.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Longer MASH drug regimen improved liver, Akero study finds

WSS

JPM: CVS says Medicare Advantage patients are impacting profits

3 trends to watch in health tech's hiring outlook for 2024

Stem cell biologist probes earliest stages of human development

Chronically ill young patients struggle to find fertility info

Pregnant women don't need prenatal multivitamins, study concludes

Lack of health data on LGBTQ+ people has serious consequences

focus

comprehensive

leisure time

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Change Healthcare: What is it, why does its cyberattack matter?

Hepatitis C has a cure — but many Americans still lack access to it

The FDA must approve intranasal treatments for anaphylaxis

ChatGPT in medicine: STAT answers readers' burning questions

GSK Flovent asthma inhalers replaced by authorized generics

23andMe had bad news about my health. I wish a person had delivered it

Antibiotic resistance and the global rise in human conflict

Tori Bowie and the unacceptable rates of Black maternal death

Medicare drug price negotiation hearing pits pharma v Biden admin

hotspot

A new approach to psychiatric drug development

Florida health officials providing scant details on measles cases

Morgan Health, with ambitious aims, wants you to know it’s still here

Families look for replacement for GSK asthma drug Flovent

J&J to buy cancer drug developer Ambrx Biopharma

Harvard's David Sinclair gets blowback over aging

entertainment

explore

explore

focus